SlipstreamJobs tracks this role from the company's public career site. Apply directly on the employer's site.
Sword Health is hiring a Head of Go-to-Market for Pulse, its AI-powered cardiometabolic care solution. This is a director-level role sitting at the intersection of product marketing, commercial strategy, and market development—one of the two most critical positions on the Pulse leadership team.
You will own three core responsibilities:
1. Build Pulse's market narrative and positioning. Develop the messaging architecture, competitive differentiation, and buyer-segment-specific positioning (employers, health plans, GLP-1 programs, pharmacy benefit managers) that makes clear why Pulse is categorically superior to incumbent solutions. This includes competitive battle cards, ROI frameworks, and proof materials that move skeptical buyers.
2. Lead and scale the commercial enablement team. Build and manage a small team of solution specialists who pair with sales reps across segments. Ensure every commercial leader can answer hard questions, handle competitive comparisons, and walk benefits VPs and health plan CMOs through the value and safety of switching to Pulse.
3. Systematically surface and pursue market opportunities. Beyond inbound leads, you will canvass the US and global markets to identify accounts, RFPs, renewal signals, and segment opportunities that would otherwise go unnoticed. You will leverage AI tooling and systematic intelligence workflows to operate at scale and speed beyond traditional GTM teams, then partner with commercial leaders to pursue and win those opportunities.
Sword Health is a clinical-centric frontier AI lab and applied AI platform reimagining healthcare delivery at scale. Since 2020, the company has expanded across Musculoskeletal, Women's Health, Cardiometabolic, and Mental Health. More than 1 million members across three continents have completed over 15 million AI sessions, helping 2,000+ enterprise clients avoid over $1 billion in unnecessary healthcare costs. Backed by $500M+ in funding from Khosla Ventures, General Catalyst, and Founders Fund, with 59 clinical studies and 43 patents, Sword is defining a new standard for AI-native healthcare.
